鼻咽癌调强放疗剂量差异对近远期疗效及OMAS、VAS评分的影响  

Influence of dosimetric difference in intensity-modulated radiotherapy on short-and long-term efficacy,OMAS and VAS scores in nasopharyngeal carcinoma

作　　者：杨芳[1] 郭汝元[1] Yang Fang;Guo Ruyuan(Department of Head and Neck Radiotherapy,Shanxi Cancer Hospital,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院放疗头颈综合科,太原030013

出　　处：《中华生物医学工程杂志》2022年第5期574-577,共4页Chinese Journal of Biomedical Engineering

摘　　要：评价调强放疗剂量差异对鼻咽癌患者近远期疗效及口腔黏膜评估量表(OMAS)评分、视觉模拟量表(VAS)评分的影响。前瞻性选择我院鼻咽癌患者120例实施不同剂量调强放疗,观察其近远期疗效及放疗后OMAS评分、VAS评分。研究发现高剂量组6、9、12个月的局部控制率(92.50%、95.00%、97.50%)明显高于低剂量组(75.00%、75.00%、77.50%),且3年、4年、5年的生存率(75.00%、60.00%、50.00%)明显高于低剂量组的生存率(45.00%、30.00%、22.50%)。适当增加调强放疗剂量可以提高鼻咽癌治疗效果。The purpose of this study was to evaluate the influence of dosimetric difference in intensity-modulated radiotherapy(IMRT)on the short-and long-term efficacy,Oral Mucositis Assessment Scale(OMAS)and visual analogue scale(VAS)scores in patients with nasopharyngeal carcinoma(NPC).The study prospectively included 120 NPC patients who received different doses of IMRT in our hospital.The short-and long-term efficacy,OMAS and VAS scores after IMRT were observed.Our study found that the 6-,9-and 12-month local control rates in the high-dose group(92.50%,95.00%,97.50%)were significantly higher than those in the low-dose group(75.00%,75.00%,77.50%).The 3-,4-and 5-year survival rates in the high-dose group(75.00%,60.00%,50.00%)were also significantly higher than those in the low-dose group(45.00%,30.00%,22.50%).In summary,proper increase in the dose of IMDT may result in improved therapeutic efficacy of NPC.

关 键 词：鼻咽癌 调强放疗 疗效 生存率 

分 类 号：R739.63[医药卫生—肿瘤]